ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "T-Lymphocyte"

  • Abstract Number: 0802 • ACR Convergence 2023

    Targeting Fibroblasts in Inflammatory Disease Using Engineered T Cells

    Samuel Kemble1, Christopher Mahony2, Charlotte Smith2, Joel Rurik3, Haig Aghajanian3, Jonathan Epstein3, Mark Coles4 and Adam Croft2, 1University Birmingham, Rugeley, United Kingdom, 2University of Birmingham, Birmingham, United Kingdom, 3University of Pennsylvania, Philadelphia, PA, 4University of Oxford, Oxford, United Kingdom

    Background/Purpose: Fibroblast activation protein alpha (FAPa) expressing fibroblasts orchestrate tissue inflammation and damage in rheumatoid arthritis (RA) as well as tissue immunity in primary Sjögren's…
  • Abstract Number: 0909 • ACR Convergence 2023

    Rab4A Controls the Depletion of IL-2 in CD4+ T Cells via Enhanced CD38 Expression: Potential Involvement in Proinflammatory Lineage Development in Systemic Lupus Erythematosus

    Joy Park1, Xiaojing Wang2, Aparna Godavarthy1, Akshay Patel2, Krakko Daniel1, Jessica Nolan1, Joanne Chilton1, Bryan Blaker1 and Andras Perl3, 1Upstate Medical University, Syracuse, NY, 2SUNY Upstate Medical University, Syracuse, NY, 3SUNY, Syracuse, NY

    Background/Purpose: HRES-1/Rab4 (Rab4A) is a small GTPase that is overexpressed in SLE patient T cells1,2, mediates the enhanced recycling of CD3 and CD4 cell surface…
  • Abstract Number: 0928 • ACR Convergence 2023

    Skewing of B Cell Receptor Repertoire in Unswitched Memory B Cells Is Associated with Disease Activity of Systemic Lupus Erythematosus and Targeted by Belimumab

    Keishi Fujio1, Mineto Ota1, Masahiro Nakano2, Yasuo Nagafuchi3, Satomi Kobayashi1, Hiroaki Hatano2, Ryochi Yoshida1, Yuko Akutsu1, Takahiro Itamiya1, Nobuhiro Ban4, Yumi Tsuchida1, Hirofumi Shoda1, Kazuhiko Yamamoto5, Kazuyoshi Ishigaki6 and Tomohisa Okamura7, 1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Laboratory for Autoimmune Diseases, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, 3Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 4Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama, Japan, 5Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, 6RIKEN, Tokyo, Japan, 7Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

    Background/Purpose: Despite the involvement of B cells in the pathogenesis of immune-mediated diseases, the biological mechanisms underlying their function are poorly understood. To address this…
  • Abstract Number: 0003 • ACR Convergence 2023

    Expanded Extrafollicular B Cells Were Improved by RTX in IgG4-related Disease

    Yusho Ishii1, Aakriti Alisha Arora1, Scott Jenks1, Iñaki Sanz2 and Arezou Khosroshahi1, 1Emory University, Atlanta, GA, 2Emory University School of Medicine, Atlanta, GA

    Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated disease characterized by fibrotic masses with expansion of IgG4-producing plasma cell in multiple organs such as pancreas, lacrimal…
  • Abstract Number: 1318 • ACR Convergence 2023

    Abatacept Modulates Both Global and Citrulline Specific T Cell Signatures: Results from Inhibition of Co-Simulation in Rheumatoid Arthritis Phase IV Trial

    Ravi Kumar Sharma1, Aysin Tulunay Virlan2, Louise Bennett3, John Cole3, Sam McAllister2, Sara Turcinov4, Samantha Miller3, Fraser Morton3, Ashley Gilmour3, Sean Kerrigan3, Anatoly Dubnovitsky1, Leonid Padyukov5, Caron Paterson3, William Kwok6, René Toes7, Lars Klareskog8, Arthur Pratt9, John Isaacs10, Sean Connolly11, Duncan Porter3, Stefan Siebert12, Iain McInnes3, Vivianne Malmström8 and Carl Goodyear3, 1Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2University of Glasgow - School of Infection & Immunity, Glasgow, United Kingdom, 3University of Glasgow, Glasgow, United Kingdom, 4Division of Rheumatology, Department of Medicine Solna, Center for Molecular Medicine, Karolinska Institutet. Theme of Inflammation and Ageing, Medical Unit Gastro, Derma, Rheuma, Karolinska University Hospital, Stockholm, Sweden, 5Karolinska Institutet, Solna, Sweden, 6Benaroya Research Institute at Virginia Mason, Seattle, WA, 7Leiden University Medical Center, Leiden, Netherlands, 8Karolinska Institutet, Stockholm, Sweden, 9Immunity and Inflammation Theme, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom, 10Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Unit, Newcastle Hospitals, Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom, 11Bristol Myers Squibb, Princeton, NJ, 12School of Infection and Immunity, University of Glasgow, Glasgow, United Kingdom

    Background/Purpose: Clinical outcomes in Rheumatoid arthritis (RA) have improved with the introduction of biological and targeted synthetic disease modifying anti-rheumatic drugs (b & tsDMARDs). Abatacept…
  • Abstract Number: 0013 • ACR Convergence 2023

    A Proliferating T Cell Signature in Blood Is Associated with Response to JAK Inhibitor Therapy in Rheumatoid Arthritis Patients

    Mehreen Elahee1, Kathryne Marks2, Ifeoluwakiisi Adejoorin2, Lin Chen2, Derrick Todd2, Jonathan Coblyn2, Elena Massarotti2, Susan Ritter2, Michael Weinblatt3, Daniel Solomon4 and Deepak Rao2, 1University of Pittsburgh Medical Center, Pittsburgh, PA, 2Brigham and Women's Hospital, Boston, MA, 3Harvard Medical School, Waban, MA, 4Brigham and Women's Hospital, Newton, MA

    Background/Purpose: There are multiple DMARDs available to treat rheumatoid arthritis (RA) yet there are no widely used predictive biomarkers to guide selection of a specific…
  • Abstract Number: 1320 • ACR Convergence 2023

    Evaluation of Circulating Levels of Helper T and Innate Lymphoid Cells Subsets in a Cohort of bDMARDs-naïve Patients with Rheumatoid Arthritis Treated with Abatacept

    Paolo Semeraro1, Fabrizio Angeli1, Alessia Caproli1, Franco Franceschini2, Paolo Airò3 and Silvia Piantoni4, 1Rheumatology and Clinical Immunology Unit, Department of Clinical and Experimental Sciences, ASST Spedali Civili and University of Brescia, Brescia, Italy, 2Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, 3Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, University of Brescia, Brescia, Italy, 4ASST Spedali Civili and University of Brescia, Brescia, Italy

    Background/Purpose: Helper T cells (Th) are key players in rheumatoid arthritis (RA). Th17 and Th17.1 have a prominent function in the early phase of inflammation,…
  • Abstract Number: 0036 • ACR Convergence 2023

    Using Genotyping and Chromatin Data in CD4+ T Cells to Nominate Causal Variants on JIA Risk Haplotypes and to Identify Their Target Genes

    Emma Haley1, gilad Barshad2, Kaiyu Jiang3, Adam He2, Edward J Rice4, Marc Sudman5, Susan Thompson6, Elizabeth Crinzi1, Charles G Danko4 and James N Jarvis7, 1Jacobs School of Medicine and Biomedical Sciences, Buffalo, NY, 2Cornell University, Ithaca, NY, 3University at Buffalo, Buffalo, NY, 4Baker Institute of Animal Health Cornell University, Ithaca, NY, 5Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 6Cincinnati Children's Hospital Medical Center/University of Cincinnati College of Medicine, Blue Ash, OH, 7University at Buffalo Jacobs School of Medicine, Buffalo, NY

    Background/Purpose: GWAS have identified multiple genetic regions that confer risk for juvenile idiopathic arthritis (JIA).However, identifying the single nucleotide polymorphisms (SNPs) that drive risk has…
  • Abstract Number: 1370 • ACR Convergence 2023

    Synthetic Glabridin Derivatives Improves Sjogren’s Syndrome by Inducing Salivary Secretion and Salivary Gland Regeneration

    Eui-Jong Kwon1, Jin-Sil Park2, Ha Yeon Jeong3, Hye Yeon Kang4, JeongWon Choi3, Mi-La Cho3 and Sung-Hwan Park5, 1Division of Rheumatology, Department of Internal Medicine, The Catholic University of Korea Seoul St. Mary's Hospital, Seocho-gu, South Korea, 2The Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, 3Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 4Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The Catholic University of Korea, Seocho-gu, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea

    Background/Purpose: Sjogren’s syndrome (SS) is a systemic autoimmune disease characterized by infiltration of lymphocytes into the exocrine gland resulting in progressive lacrimal and salivary estruction…
  • Abstract Number: 1180 • ACR Convergence 2022

    Deficiency and Altered Phenotype of Mucosal-associated Invariant T Cells in Systemic Sclerosis

    Manon Lesturgie-Talarek1, Virginie Gonzalez1, Camelia Frantz2, Noémie Sénot1, Zouriatou Gouda1, Camille Rousseau1, Lucie Beaudoin1, Agnès Lehuen1, Jérôme Avouac3 and Yannick Allanore4, 1INSERM U1016, Institut Cochin, Paris, France, 2Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, 3University of Paris, Paris, France, 4Department of Rheumatology A, Descartes University, APHP, Cochin Hospital, Paris, France, Paris, France

    Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of the skin and internal organs such as the lung. Mucosal-associated invariant T (MAIT)…
  • Abstract Number: 1705 • ACR Convergence 2022

    Peptidoglycan Amplifies CD4+ T Cell Activation by MHCII+ Fibroblast-like Synoviocytes in an in Vitro Model of Lyme Arthritis

    Joseph Rouse1, Amanda Wahhab1, Rebecca Danner1, Brandon Jutras2, Adam Edelstein3, Klemen Strle4 and Robert Lochhead5, 1Medical College of Wisconsin, Milwaukee, WI, 2Virginia Tech, Blacksburg, VA, 3Northwestern Medicine, Chicago, IL, 4Wadsworth Center, Albany, NY, 5Medical College of Wisconsin, Germantown, WI

    Background/Purpose: Lyme arthritis (LA), caused by infection with Borrelia burgdorferi (Bb), is characterized by proliferative synovitis accompanied by dysregulated autoimmune Th1 responses. Fibroblast-like synoviocytes (FLS)…
  • Abstract Number: 1739 • ACR Convergence 2022

    Single-Cell Characterization of the TCR Repertoire Across Tissue and Blood in Rheumatoid Arthritis

    Garrett Dunlap1, Aaron Wagner2, Nida Meednu3, Anna Jonsson4, Fan Zhang5, Kevin Wei6, Paul Utz7, William Robinson7, Holden Maecker7, Judith James8, Joel Guthridge8, S. Louis Bridges, Jr.9, Laura Donlin9, Susan Goodman9, Edward DiCarlo9, Vivian Bykerk9, Christopher Ritchlin10, Darren Tabechian11, James Lederer4, Ellen Gravallese12, Mandy McGeachy13, Gary S. Firestein14, Peter Gregersen15, Diane Horowitz16, David Boyle17, Laura Geraldino-Pardilla18, Harris Perlman19, Arthur Mandelin20, Joan Bathon18, Laura Hughes21, V. Michael Holers22, Kevin D Deane23, Larry Moreland22, Andrew Filer24, Costantino Pitzalis25, Lindsy Forbess26, Ami Ben-artzi27, Karen Salomon-Escoto28, Soumya Raychaudhuri4, Michael Brenner12, Accelerating Medicines Partership (AMP) RA/SLE Network29, Andrew McDavid2, Jennifer Anolik3 and Deepak Rao4, 1Harvard University, Boston, MA, 2University of Rochester, Rochester, NY, 3University of Rochester Medical center, Rochester, NY, 4Brigham and Women's Hospital, Boston, MA, 5University of Colorado, Aurora, CO, 6Brigham and Women's Hospital and Harvard Medical School, Boston, MA, 7Stanford University School of Medicine, Palo Alto, CA, 8Oklahoma Medical Research Foundation, Oklahoma City, OK, 9Hospital for Special Surgery, New York, NY, 10Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, 11URMC, Rochester, NY, 12Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 13University of Pittsburgh, Pittsburgh, PA, 14University of California, San Diego, San Diego, CA, 15The Feinstein Inst for Med Research, Larchmont, NY, 16Northwell Health, Jericho, NY, 17UCSD, La Jolla, CA, 18Columbia University, New York, NY, 19Northwestern University, Chicago, IL, 20Northwestern University Feinberg School of Medicine, Chicago, IL, 21University of Alabama at Birmingham, Birmingham, AL, 22University of Colorado, Denver, CO, 23University of Colorado Denver Anschutz Medical Campus, Denver, CO, 24University of Birmingham, Birmingham, United Kingdom, 25Queen Mary University of London, London, United Kingdom, 26Cedars-Sinai Medical Center, Los Angeles, CA, 27Ami Ben-Artzi, MD Inc., Beverly Hills, CA, 28University of Massachusetts Medical School, Worcester, MA, 29National Institutes of Health, Washington, DC

    Background/Purpose: In rheumatoid arthritis (RA), T cells represent a large proportion of the immune population present in inflamed joint synovium, and subsets of both CD4+…
  • Abstract Number: 1743 • ACR Convergence 2022

    Identification of Immune Cell Types in the Peripheral Blood of Rheumatoid Arthritis Patients Associated with Susceptibility and Response to Treatment

    Maria Christofi1, Ben Mulhearn2, Lysette Marshall1, Megan Sutcliffe1, Darren Plant1, Kimme Hyrich1, Ann Morgan3, Anthony Wilson4, John D Isaacs5, Soumya Raychaudhuri6, Anne Barton1 and Sebastien Viatte1, 1The University of Manchester, Manchester, United Kingdom, 2Royal United Hospital Bath | University of Bath, Bath, United Kingdom, 3University of Leeds, Leeds, United Kingdom, 4University College Dublin, Dublin, Ireland, 5Institute for Translational and Clinical Research, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Rheumatoid arthritis (RA) is a complex immune mediated disease that affects 1% of the population. Even with modern therapeutic strategies, many patients with RA…
  • Abstract Number: 1744 • ACR Convergence 2022

    Immune Responses to mRNA Vaccines Against SARS-CoV-2 in Patients with Immune-mediated Inflammatory Rheumatic Diseases

    Cristiana Sieiro Santos1, Sara Calleja Antolín1, Clara Moriano Morales2, Carolina Álvarez Castro1, Elvira Díez Álvarez1 and Jose Maria Ruiz de Morales1, 1Complejo Asistencial Universitario de León, León, Spain, 2Hospital León, León, Spain

    Background/Purpose: Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated extraordinary efficacy…
  • Abstract Number: 1747 • ACR Convergence 2022

    Changes in the Number and Phenotype of Citrullinated-Antigen Specific T Cells Correlate with Treatment Outcome in Seropositive Rheumatoid Arthritis

    Cliff Rims1, Virginia Muir1, Anne Hocking1, Sylvia Posso1, Heather Bukiri2, Jeffrey Carlin3, Bernard Ng4, Peter Linsley1, Eddie James5 and Jane Buckner5, 1Benaroya Research Institute, Seattle, WA, 2University of California Los Angeles, Los Angeles, CA, 3Virginia Mason Medical Center, Seattle, WA, 4VA Puget Sound HCS, Seattle, WA, 5Benaroya Research Institute at Virginia Mason, Seattle, WA

    Background/Purpose: In Rheumatoid arthritis (RA) citrullinated antigen reactive T cells are key drivers of disease, but knowledge about their relative number and phenotype remains limited.…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology